CDKN2B-AS1 and cancer: Upregulated ANRIL expression levels have been found to be linked with cancers such as lung, stomach, breast, ovarian, cervical, colorectal, bladder, thyroid, brain, osteosarcoma, myeloma, prostate, endometrial, renal, leukaemia, melanoma, retinoblastoma, and hepatocellular carcinoma [248].